Evidence map›Paper›PMID 19534719›Full record

ArticleCurrent neurovascular research2009

The pro-apoptotic substance thapsigargin selectively stimulates re-growth of brain capillaries.

Celine Ullrich, Christian Humpel

Abstract read
In one paragraph

Article in Current neurovascular research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Celine UllrichLaboratory of Psychiatry and Exp. Alzheimer's Research, Department of Psychiatry, Innsbruck Medical University, Austria.
Christian Humpel
Innsbruck Medical University · AT

Funding

Austrian Science Fund FWF P 19122
6 · The paper itself

Abstract

Thapsigargin is a pro-apoptotic chemical, which has been shown to be useful to study cell death of cholinergic or dopaminergic neurons, or cells, which degenerate in Alzheimer's disease or Parkinson's disease, respectively. The aim of the present work was to study the effects of thapsigargin in the well established organotypic brain co-slice model composed of the basal nucleus of Meynert (nBM), ventral mesencephalon (vMes), dorsal striatum (dStr) and parietal cortex (Ctx). Cholinergic acetyltransferase-positive neurons in the nBM and dStr and dopaminergic tyrosine hydroxylase-positive neurons in the vMes survived, when cultured for 4 weeks with nerve growth factor and glial cell line-derived neurotrophic factor. Nerve fibers of cholinergic nBM neurons grew into the cortex and dopaminergic nerve fibers sprouted into dopamine D2 receptor-positive dStr. The whole co-slice contained a dense laminin-positive capillary network. Treatment of co-cultures with 3 microM thapsigargin for 24 hr significantly decreased the number of cholinergic neurons and dopaminergic neurons. This cell death displayed apoptotic DAPI-positive malformed nuclei and enhanced TUNEL-positive cells. Thapsigargin selectively stimulated the laminin-positive capillary growth between the nBM and Ctx. In conclusion, the induced cell death of cholinergic and dopaminergic neurons may be accompanied by enhanced angiogenic activity.

Indexed as

AcetylcholinesteraseAnimalsAnimals, NewbornCapillariesCell CountCell DeathCerebral CortexCoculture TechniquesCorpus StriatumEnzyme InhibitorsIndolesIn Situ Nick-End LabelingLamininNeuronsOrgan Culture TechniquesRatsAcetylcholinesteraseDAPIEnzyme InhibitorsIndolesLamininThapsigarginTyrosine 3-Monooxygenase

Identifiers

PMID19534719
PMCPMC4311392
OpenAlexW1989806442

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.